Silence Therapeutics (NASDAQ:SLN) Given Buy Rating at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Silence Therapeutics (NASDAQ:SLN) in a research note released on Friday morning,Benzinga reports. The brokerage currently has a $75.00 target price on the stock.

Several other research analysts have also recently weighed in on the stock. Chardan Capital reaffirmed a “buy” rating and issued a $55.00 price target on shares of Silence Therapeutics in a report on Tuesday, December 10th. BMO Capital Markets reduced their target price on Silence Therapeutics from $67.00 to $25.00 and set an “outperform” rating on the stock in a research note on Tuesday. Morgan Stanley reduced their target price on Silence Therapeutics from $49.00 to $45.00 and set an “overweight” rating on the stock in a research note on Wednesday. The Goldman Sachs Group reduced their target price on Silence Therapeutics from $6.00 to $4.00 and set a “sell” rating on the stock in a research note on Tuesday. Finally, William Blair reissued an “outperform” rating on shares of Silence Therapeutics in a research note on Tuesday, November 19th. One equities research analyst has rated the stock with a sell rating and six have assigned a buy rating to the stock. According to data from MarketBeat.com, Silence Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $40.67.

Silence Therapeutics Stock Performance

Silence Therapeutics stock opened at $4.85 on Friday. The stock has a market cap of $145.16 million, a P/E ratio of -3.09 and a beta of 1.08. Silence Therapeutics has a fifty-two week low of $4.06 and a fifty-two week high of $27.72. The firm’s fifty day moving average price is $5.44 and its 200-day moving average price is $11.48.

Institutional Trading of Silence Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. Eventide Asset Management LLC purchased a new stake in Silence Therapeutics during the third quarter valued at about $11,635,000. Parkman Healthcare Partners LLC boosted its position in Silence Therapeutics by 71.8% during the third quarter. Parkman Healthcare Partners LLC now owns 497,870 shares of the company’s stock valued at $9,051,000 after buying an additional 208,029 shares during the period. Point72 Asset Management L.P. boosted its position in Silence Therapeutics by 219.3% during the third quarter. Point72 Asset Management L.P. now owns 467,800 shares of the company’s stock valued at $8,505,000 after buying an additional 321,300 shares during the period. Janus Henderson Group PLC boosted its position in Silence Therapeutics by 32.8% during the third quarter. Janus Henderson Group PLC now owns 1,087,228 shares of the company’s stock valued at $19,798,000 after buying an additional 268,250 shares during the period. Finally, Verition Fund Management LLC purchased a new stake in shares of Silence Therapeutics during the third quarter worth about $207,000. 98.73% of the stock is currently owned by hedge funds and other institutional investors.

Silence Therapeutics Company Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.